The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus - PubMed
5 hours ago
- #mood disorders
- #psychopharmacology
- #deprescribing
- The ASCP task force developed expert consensus on deprescribing psychotropic medications for mood disorders.
- Consensus was reached on 20 out of 32 statements across seven thematic areas.
- In MDD, antidepressants should be discontinued if mechanisms are duplicative, trials produce ≤25% improvement, or efficacy loss cannot be regained.
- Indefinite antidepressant maintenance in MDD was favored after three or more lifetime episodes.
- In bipolar disorder, antidepressant deprescribing was favored in cases of rapid cycling, mixed features, or emerging mania/hypomania symptoms.
- Deprescribing antipsychotics was favored in nonpsychotic mood disorders if they caused significant weight gain or tardive dyskinesia.
- Deprescribing to achieve a medication-free status was considered inappropriate for bipolar type 1 but not necessarily for bipolar type 2 disorder.
- Individualized circumstances should guide psychopharmacology management, with cautious deprescribing when clinical presentations misalign with existing therapies.